Copyright
©The Author(s) 2017.
World J Gastroenterol. Nov 28, 2017; 23(44): 7899-7905
Published online Nov 28, 2017. doi: 10.3748/wjg.v23.i44.7899
Published online Nov 28, 2017. doi: 10.3748/wjg.v23.i44.7899
Table 5 Association of baseline characteristics of the patients with sustained virological response treated with sofosbuvir + ribavirin + peg-interferon-alfa-2a (Second group) n (%)
| Time point | Viral load (n = 528) | ETR (n = 526), overall ETR 0.9962 | SVR (n = 515), overall SVR 0.9791 | Relapse (n = 11), overall relapse rate = 2.09% |
| Baseline (d-0) | ≤ 2 MIU/mL (n = 316) | 316 (100) | 313 (99.05) | 3 (0.95) |
| > 2 MIU/mL (n = 212) | 210 (99.06) | 202 (96.19) | 8 (3.81) | |
| RVR (weeks-4) | Negative (n = 116) | 116 (100) | 116 (100) | 0 (0) |
| ≥ 2 log drop (n = 380) | 380 (100) | 376 (98.95) | 4 (1.05) | |
| < 2 log drop (n = 32) | 30 (93.75) | 23 (76.67) | 7 (23.33) |
- Citation: Iqbal S, Yousuf MH, Yousaf MI. Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study. World J Gastroenterol 2017; 23(44): 7899-7905
- URL: https://www.wjgnet.com/1007-9327/full/v23/i44/7899.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i44.7899